Tomorrow Capital leads $2.7 mm fundraise for kidney care startup VitusCare

The fresh capital injection will empower VitusCare to aggressively expand its operations, with a targeted focus on deeper penetration into 'Bharat', it added

Fundraising via QIPs gains traction in '24 market
Illustration: Binay Sinha
Press Trust of India New Delhi
2 min read Last Updated : Apr 16 2024 | 5:29 PM IST

Venture capital fund Tomorrow Capital on Tuesday said it has led a USD 2.7 million (over Rs 20 crore) fundraise for VitusCare, a kidney care startup based in Gurugram.

In addition to Tomorrow Capital's contribution, the Series A funding round saw participation from existing investor 1Crowd, alongside support from 3i Partners and a consortium of angel investors, totalling approximately USD 5 million in funding across all the funding rounds, the company said in a statement.

The fresh capital injection will empower VitusCare to aggressively expand its operations, with a targeted focus on deeper penetration into 'Bharat', it added.
 

ALSO READ: Amazon Pay explores credit on UPI through collaboration with NPCI

"As the prevalence of lifestyle-related disorders such as diabetes and hypertension continue to rise, the demand for kidney-related services is poised to increase exponentially. VitusCare's innovative approach and impressive growth trajectory align perfectly with our mission to invest in solutions that make a meaningful impact on public health," Tomorrow Capital CEO Rohini Prakash said.

VitusCare has around 30 centres currently operational across North India. It collaborates with existing hospitals to ensure seamless delivery of end-to-end dialysis services, including equipment provision, skilled technicians and patient care.

"Tomorrow Capital's investment marks a significant milestone for VitusCare as we embark on our mission to deliver high-quality, patient-centric care to underserved regions of India. This fundraise will be pivotal in accelerating our expansion efforts and scaling our operations to meet the growing demand for quality dialysis care," VitusCare Co-Founder & CEO Prabhat Shrivastava said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Venture Capitalventure capitalistsFundraisingpublic health

First Published: Apr 16 2024 | 5:29 PM IST

Next Story